TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19671016

Group type: EXPERIMENTAL
Intervention: Parenteral procaine benzyl penicillin and an aminoglycoside
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community-acquired neonatal bacteremia incidence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pathogen identification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibiotic resistance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infection timing
Number of subjects: 0
Study: 19671733

Group type: EXPERIMENTAL
Intervention: Oleandrin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Knocking down alpha3 isoform with alpha3 siRNA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Increasing expression of alpha1 isoform through transient transfection of alpha1 cDNA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rodent cancer cells
Number of subjects: 0
Study: 19675988

Group type: EXPERIMENTAL
Intervention: Powered knee prosthesis with two series-elastic actuators in an agonist-antagonist arrangement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weight- and height-matched nonamputee
Number of subjects: 0
Study: 19676128

Group type: COMPARATOR
Intervention: None (no coffee consumption)
Number of subjects: 766

Group type: COMPARATOR
Intervention: Less than 1 cup/day
Number of subjects: 766

Group type: COMPARATOR
Intervention: 1 to fewer than 3 cups/day
Number of subjects: 766

Group type: COMPARATOR
Intervention: 3 or more cups/day
Number of subjects: 766
Study: 19679246

Group type: EXPERIMENTAL
Intervention: MitraClip system
Number of subjects: 107
Study: 19679693

Group type: EXPERIMENTAL
Intervention: Resting MPAP above the median (17 mm Hg)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Resting pulmonary vascular resistance
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: MPAP above the median at 25W and 50W
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cardiac index at peak exercise
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Pulmonary vascular resistance at peak exercise
Number of subjects: 29
Study: 19679883

Group type: EXPERIMENTAL
Intervention: Subcutaneous rituximab (20 mg, thrice weekly for up to 12 weeks)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Intravenous rituximab (thrice-weekly, fractionated-dose)
Number of subjects: 4
Study: 19683108

Group type: EXPERIMENTAL
Intervention: Emergency endoscopy in patients with CAD
Number of subjects: 100
Study: 19683270

Group type: EXPERIMENTAL
Intervention: Confocal laser endomicroscopy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard hematoxylin and eosin analysis
Number of subjects: 27
Study: 19685102

Group type: EXPERIMENTAL
Intervention: T2DM patients with myocardial ischemia
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: T2DM patients with carotid arterial disease
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: T2DM patients with peripheral arterial disease
Number of subjects: 305

Group type: COMPARATOR
Intervention: Reference subjects (nondiabetic)
Number of subjects: 305
Study: 19687399

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with porfimer sodium (2 mg/kg, injected intravenously 48 hours before treatment) and light at 630 nm (50 J/cm² for dysplasia and CIS, 75 J/cm² for carcinoma)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with porfimer sodium
Number of subjects: 30
Study: 19687424

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 62
Study: 19688336

Group type: EXPERIMENTAL
Intervention: Cognitive function (normal, mild dysfunction, severe dysfunction)
Number of subjects: 11140

Group type: EXPERIMENTAL
Intervention: Severe cognitive dysfunction
Number of subjects: 11140
Study: 19689789

Group type: EXPERIMENTAL
Intervention: Neoadjuvant anti-estrogen therapy (Tamoxifen for premenopausal women, Letrozole for postmenopausal women)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (patients who did not undergo preoperative anti-estrogenic treatment)
Number of subjects: 23
Study: 19690058

Group type: EXPERIMENTAL
Intervention: Capecitabine 1000 mg/m(2) b.i.d. for 2 weeks followed by capecitabine 575-650 mg/m(2) b.i.d. and cisplatin 20-25 mg/m(2) i.v. weekly during chemoradiotherapy
Number of subjects: 31
Study: 19692493

Group type: EXPERIMENTAL
Intervention: Hydrolyzed casein (HC)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Intact casein (IC)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both IC and HC
Number of subjects: 21
Study: 19692879

Group type: EXPERIMENTAL
Intervention: Harmonic scalpel (HA) during videolaparocholecystectomy (VLC)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (VLC without HA)
Number of subjects: 101
Study: 19694588

Group type: EXPERIMENTAL
Intervention: Telemedicine initiative for stroke care
Number of subjects: 24

Group type: COMPARATOR
Intervention: Current stroke care practices
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Proposed 5-year stroke telemedicine plan
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Geographic coverage and operating costs
Number of subjects: 24
Study: 19695539

Group type: EXPERIMENTAL
Intervention: TAXUS Express stents implantation
Number of subjects: 441
Study: 19696651

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy in acute HIV-1 infection
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy in recent HIV-1 infection
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Baseline viral load <100,000/ml
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Baseline viral load >100,000/ml
Number of subjects: 121
Study: 19697416

Group type: EXPERIMENTAL
Intervention: Preservative-free (PF) hepatitis B vaccine
Number of subjects: 541

Group type: COMPARATOR
Intervention: Preservative-containing (PC) hepatitis B vaccine
Number of subjects: 541

Group type: COMPARATOR
Intervention: Low-preservative (LP) hepatitis B vaccine
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Follow-up study after 6 years
Number of subjects: 541
Study: 19698154

Group type: EXPERIMENTAL
Intervention: Internet-mediated walking program (Stepping Up to Health)
Number of subjects: 880
Study: 19698185

Group type: EXPERIMENTAL
Intervention: Implementation of the Chronic Care Model (CCM) program for type 2 diabetes patients.
Number of subjects: 2300

Group type: EXPERIMENTAL
Intervention: Establishment of a local steering group and appointment of a program manager.
Number of subjects: 2300

Group type: EXPERIMENTAL
Intervention: Well-trained and motivated care providers investing in quality improvement.
Number of subjects: 2300

Group type: EXPERIMENTAL
Intervention: Complexity of the intervention, lack of quality data, inadequate information technology support, lack of commitment procedures, uncertainty about sustainable funding.
Number of subjects: 2300
Study: 19698816

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) 90 mcg/ethinyl estradiol (EE) 20 mcg, taken continuously for three 28-day intervals.
Number of subjects: 58
Study: 19700662

Group type: EXPERIMENTAL
Intervention: Cytotoxic T lymphocyte (CTL) therapy with specificity for Epstein-Barr virus (EBV) and adenovirus (5 x 10(6)-1.35 x 10(8) cells/m(2))
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Cytotoxic T lymphocyte (CTL) therapy with specificity for adenovirus
Number of subjects: 13
Study: 19701032

Group type: EXPERIMENTAL
Intervention: Postoperative pelvic and groin radiation (45-50 Gy, n=59)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Ipsilateral pelvic node resection (n=55)
Number of subjects: 114
Study: 19703299

Group type: EXPERIMENTAL
Intervention: Atomoxetine (0.5-1.2 mg/kg/day)
Number of subjects: 159
Study: 19703304

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week subcutaneously
Number of subjects: 307

Group type: COMPARATOR
Intervention: Control group (OASIS cohort)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Control group (OASIS-Eligible cohort)
Number of subjects: 307
Study: 19704093

Group type: EXPERIMENTAL
Intervention: 320-row computed tomography (CT)
Number of subjects: 30
Study: 19704101

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Left Ventricular Mass Index
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Decreased Myocardial Perfusion
Number of subjects: 1100
Study: 19706858

Group type: EXPERIMENTAL
Intervention: Clopidogrel treatment for 7 days
Number of subjects: 429
Study: 19706886

Group type: EXPERIMENTAL
Intervention: 2 partially HLA-matched UCB units
Number of subjects: 177

Group type: COMPARATOR
Intervention: 1 partially HLA-matched UCB unit
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Advanced disease patients (>= CR3)
Number of subjects: 177
Study: 19707564

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine
Number of subjects: 99
Study: 19708226

Group type: EXPERIMENTAL
Intervention: Noninvasive and invasive findings (clinical interview, 12-lead ECG, 24-h ECG, echocardiogram)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Electrophysiological study, pacemaker, implantable cardioverter defibrillator or loop recorder implantation
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Prognostic factors tested for association with endpoints
Number of subjects: 500
Study: 19709990

Group type: EXPERIMENTAL
Intervention: Online dietary intervention (MENU)
Number of subjects: 28460
Study: 19710484

Group type: EXPERIMENTAL
Intervention: Abbott-Architect Troponin I
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Roche High-Sensitive Troponin T
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Roche Troponin I
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Siemens Troponin I Ultra
Number of subjects: 718

Group type: COMPARATOR
Intervention: Standard assay (Roche Troponin T)
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Sensitive assays (within 3 hours of chest pain onset)
Number of subjects: 718
Study: 19712484

Group type: EXPERIMENTAL
Intervention: Training plus study supports (job aids, non-financial incentives, and supervision)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Training plus usual supports
Number of subjects: 301

Group type: COMPARATOR
Intervention: Untrained health workers
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Increased supervision frequency
Number of subjects: 301
Study: 19712798

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 1748

Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 1748
Study: 19712979

Group type: EXPERIMENTAL
Intervention: Escitalopram, 10 mg for 49 days
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Escitalopram, 10 mg after 1 week
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: ATR and early Ham-D(17) changes
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Clinician prediction based on global impression at day 7
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Serum drug levels and genetic polymorphisms (5HTTLPR and 5HT2a)
Number of subjects: 375
Study: 19713195

Group type: EXPERIMENTAL
Intervention: Secondary Descemet stripping endothelial keratoplasty (DSEK)
Number of subjects: 10
Study: 19713456

Group type: EXPERIMENTAL
Intervention: Bortezomib (1.3 mg/m2)
Number of subjects: 23
Study: 19714615

Group type: EXPERIMENTAL
Intervention: Belimumab (1, 4, 10 mg/kg) plus standard of care therapy (SOC)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Placebo plus standard of care therapy (SOC)
Number of subjects: 449
Study: 19716045

Group type: EXPERIMENTAL
Intervention: C2 levels in lung transplant recipients (T1 vs T3)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: C2 levels in lung transplant recipients
Number of subjects: 191
Study: 19717268

Group type: EXPERIMENTAL
Intervention: Emergency tourniquet use
Number of subjects: 499
Study: 19717473

Group type: EXPERIMENTAL
Intervention: Shorter 3 and 4 repeat alleles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4 allele
Number of subjects: 0
Study: 19718477

Group type: EXPERIMENTAL
Intervention: PTX3 (upper quartiles)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BNP (upper quartiles)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of PTX3 and BNP
Number of subjects: 0

Group type: COMPARATOR
Intervention: hsCRP
Number of subjects: 0
Study: 19719485

Group type: EXPERIMENTAL
Intervention: Attain Model 4193 LV lead (Medtronic, Inc)
Number of subjects: 1070
Study: 19720420

Group type: EXPERIMENTAL
Intervention: Hispanic patients
Number of subjects: 1268

Group type: EXPERIMENTAL
Intervention: African American patients
Number of subjects: 1268

Group type: COMPARATOR
Intervention: Non-Hispanic White patients
Number of subjects: 1268

Group type: EXPERIMENTAL
Intervention: Diastolic BP increase (1.13 per 5 mm Hg)
Number of subjects: 1268

Group type: EXPERIMENTAL
Intervention: Amputation
Number of subjects: 1268

Group type: EXPERIMENTAL
Intervention: Retinopathy severity
Number of subjects: 1268
Study: 19720904

Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg/d (5 mg/d if baseline platelet count < 100 x 10(9)/L) on days 1 through 21 of a 28-day cycle for six cycles, plus prednisone 30 mg/d during cycle 1, 15 mg/d during cycle 2, and 15 mg/d every other day during cycle 3.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lenalidomide and prednisone combination therapy
Number of subjects: 40
Study: 19720915

Group type: EXPERIMENTAL
Intervention: Paclitaxel (80 mg/m(2) once weekly during postoperative weeks 2, 3, and 4) followed by concurrent Paclitaxel (30 mg/m(2)) and Cisplatin (20 mg/m(2)) once weekly during the last 3 weeks of RT (60 Gy over 6 weeks).
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Paclitaxel and Cisplatin with radiation therapy (RT).
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard postoperative chemoradiotherapy (RTOG 9501).
Number of subjects: 70
Study: 19720924

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg twice a day
Number of subjects: 115
Study: 19720923

Group type: EXPERIMENTAL
Intervention: Concurrent trastuzumab and HER2/neu-specific vaccination
Number of subjects: 22
Study: 19721480

Group type: EXPERIMENTAL
Intervention: Pegylated interferon (180 microg weekly) and ribavirin (800 mg daily) for 14 weeks
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pegylated interferon and ribavirin treatment
Number of subjects: 8
Study: 19723786

Group type: EXPERIMENTAL
Intervention: Fluoxetine plus CBT
Number of subjects: 0

Group type: COMPARATOR
Intervention: CBT monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluoxetine monotherapy
Number of subjects: 0
Study: 19725960

Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin (20 mg/m2) and prolonged Temozolomide (75 mg/m2 during radiotherapy, 150-200 mg/m2 on days 1-5 of each 28-day cycle) with radiotherapy (60 Gy)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin (20 mg/m2) and prolonged Temozolomide with radiotherapy
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin and prolonged Temozolomide with radiotherapy
Number of subjects: 63
Study: 19725979

Group type: EXPERIMENTAL
Intervention: Whole Day First Grade Program (WD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard first-grade program (SC)
Number of subjects: 0
Study: 19726437

Group type: EXPERIMENTAL
Intervention: Thrombectomy
Number of subjects: 2686

Group type: EXPERIMENTAL
Intervention: Thrombectomy in patients treated with IIb/IIIa-inhibitors
Number of subjects: 2686

Group type: EXPERIMENTAL
Intervention: Manual thrombectomy
Number of subjects: 2686
Study: 19726763

Group type: EXPERIMENTAL
Intervention: GDC-0449 (150 mg per day)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: GDC-0449 (270 mg per day)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: GDC-0449 (540 mg per day)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: GDC-0449
Number of subjects: 33
Study: 19727007

Group type: EXPERIMENTAL
Intervention: Direct Renin Inhibitors (DRIs)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Direct Renin Inhibitors (DRIs) added to optimal heart failure treatment
Number of subjects: 52

Group type: COMPARATOR
Intervention: Early generation Direct Renin Inhibitors (DRIs)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Recent Direct Renin Inhibitors (DRIs)
Number of subjects: 52
Study: 19727208

Group type: EXPERIMENTAL
Intervention: Granulocyte colony stimulating factor (G-CSF)
Number of subjects: 1200
Study: 19727657

Group type: EXPERIMENTAL
Intervention: Polymorphisms rs34861192 and rs3745368 of RETN
Number of subjects: 3133

Group type: EXPERIMENTAL
Intervention: Plasma resistin level
Number of subjects: 3133
Study: 19727665

Group type: EXPERIMENTAL
Intervention: s.c. recombinant methionyl human leptin
Number of subjects: 48
Study: 19727744

Group type: EXPERIMENTAL
Intervention: Automated whole breast ultrasound (AWBU) plus mammography
Number of subjects: 4419

Group type: COMPARATOR
Intervention: Mammography alone
Number of subjects: 4419

Group type: EXPERIMENTAL
Intervention: Automated whole breast ultrasound (AWBU)
Number of subjects: 4419
Study: 19728876

Group type: EXPERIMENTAL
Intervention: Volume expansion (VE) with 500 mL of synthetic colloid
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: DeltaVpeakbrach >10%
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: DeltaPPrad >10%
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: DeltaSVVigileo >11%
Number of subjects: 38
Study: 19729666

Group type: EXPERIMENTAL
Intervention: mDC1 and mDC2
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: mDC2
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: pDC
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: mDC1, mDC2, pDC
Number of subjects: 42
Study: 19731245

Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted gastrectomy (LAG)
Number of subjects: 106
Study: 19731330

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (20 mg/kg/day for 2 years)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 19734762

Group type: EXPERIMENTAL
Intervention: Baseline ocular features (drusen size, focal hyperpigmentation, nonfoveal geographic atrophy)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Follow-up angiograms
Number of subjects: 370

Group type: COMPARATOR
Intervention: Nonocular characteristics (age, gender, history of hypertension, smoking)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Ocular features of the study eye at baseline (lesion composition, lesion size, visual acuity)
Number of subjects: 370
Study: 19738014

Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir at 5 mg/kg of body weight for 5 days, followed by oral valganciclovir at 900 mg for 16 days, both twice daily with dose adjustment for renal function.
Number of subjects: 382
Study: 19738136

Group type: EXPERIMENTAL
Intervention: Tecarfarin (ATI-5923)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 66
Study: 19738484

Group type: EXPERIMENTAL
Intervention: HIV infected individuals
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: HIV infected individuals with CD4 < 200
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: HIV infected individuals with CD4 200-350
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: HIV infected individuals with CD4 > 350
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: HIV infected individuals (current smokers)
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: HIV infected individuals (older age)
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: HIV infected individuals (baseline CD4 count)
Number of subjects: 922

Group type: COMPARATOR
Intervention: HIV infected individuals compared to controls
Number of subjects: 922
Study: 19740906

Group type: EXPERIMENTAL
Intervention: Tumour necrosis factor alpha inhibitors (TNFalpha) - infliximab (n=41), etanercept (n=13), adalimumab (n=6)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: BASDAI
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CRP
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Change in BASDAI
Number of subjects: 60
Study: 19740972

Group type: EXPERIMENTAL
Intervention: Obese adults
Number of subjects: 36

Group type: COMPARATOR
Intervention: Normal-weight adults
Number of subjects: 36
Study: 19741187

Group type: EXPERIMENTAL
Intervention: Enhanced diabetes care program addressing literacy and numeracy
Number of subjects: 198

Group type: COMPARATOR
Intervention: Existing enhanced diabetes care programs
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 198
Study: 19741558

Group type: EXPERIMENTAL
Intervention: Symptomatic convergence insufficiency with parent report of ADHD
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Symptomatic convergence insufficiency with parent report of no ADHD
Number of subjects: 261

Group type: COMPARATOR
Intervention: Normal binocular vision (NBV)
Number of subjects: 261
Study: 19744339

Group type: EXPERIMENTAL
Intervention: Nurse-initiated intervention, which couples low-intensity inpatient counseling with sustained proactive telephone counseling.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nurse training in delivery of bedside cessation counseling, electronic medical record tools, computerized referral for proactive telephone counseling, and use of internal nursing facilitators.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nurse-initiated intervention.
Number of subjects: 0
Study: 19745067

Group type: EXPERIMENTAL
Intervention: Pentostatin
Number of subjects: 51
Study: 19747748

Group type: EXPERIMENTAL
Intervention: Fasting glucose variability
Number of subjects: 0
Study: 19750065

Group type: EXPERIMENTAL
Intervention: Computerized Decision Support System (CDSS) for MDD treatment
Number of subjects: 55

Group type: COMPARATOR
Intervention: Usual care for MDD treatment
Number of subjects: 55
Study: 19751237

Group type: EXPERIMENTAL
Intervention: Rituximab (4 weekly doses)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Minor response (25-50% IgM reduction)
Number of subjects: 69
Study: 19752173

Group type: EXPERIMENTAL
Intervention: Intervention trial (specific intervention details not provided)
Number of subjects: 664

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 664
Study: 19752422

Group type: EXPERIMENTAL
Intervention: Individuals of African descent
Number of subjects: 1221

Group type: COMPARATOR
Intervention: Individuals of European descent
Number of subjects: 1221
Study: 19752530

Group type: EXPERIMENTAL
Intervention: Elevated uric acid group (>6 mg/dl)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Normal uric acid group (≤6 mg/dl)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Elevated preoperative uric acid
Number of subjects: 58
Study: 19753491

Group type: EXPERIMENTAL
Intervention: Trypanocidal treatment with benznidazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antitrypanosomal therapy with benznidazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0